Clin Colon Rectal Surg 2007; 20(3): 190-202
DOI: 10.1055/s-2007-984863
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Total Mesorectal Excision: What Are We Doing?

David B. Stewart1 , David W. Dietz1
  • 1Section of Colon and Rectal Surgery, Division of Surgery, Washington University School of Medicine, Barnes-Jewish-Christian Hospital, St. Louis, Missouri
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Juli 2007 (online)

Preview

ABSTRACT

The introduction of total mesorectal excision (TME) for rectal cancer has reduced local recurrence rates and improved oncologic outcomes, although complication rates such as anastomotic leak have also been a consequence. With the advent of neoadjuvant therapy for rectal cancer, many are questioning how this development may change the role of TME. This review presents a history of how TME evolved and a description of this technique. Complication rates, the impact of neoadjuvant therapy on local recurrence, variations of TME such as nerve-sparing proctectomy and cancer-specific mesorectal excision, and a review of functional outcomes for various methods of reconstruction are presented.

REFERENCES

David W DietzM.D. 

Washington University School of Medicine

660 S. Euclid Ave., Campus Box 8109, St. Louis, MO 63110

eMail: dietzd@wudosis.wustl.edu